Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Cuzick

Showing results (271-280 of 367) with videos related to

Pageof 37
Sort By:
NPJ Breast Cancer|February 13, 2021
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®Richard Buus, Zsolt Szijgyarto, Eugene F Schuster, et al.
Proceedings of Spie--The International Society for Optical Engineering|December 20, 2021
The impact of using weight estimated from mammographic images <i>vs</i> self-reported weight on breast cancer risk calculationKalyani P Nair, Elaine F Harkness, Soujanya Gadde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC studyMitch Dowsett, Jack Cuzick, Christopher Wale, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 23, 2014
Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemopreventionD Gareth Evans, Adam R Brentnall, Michelle Harvie, et al.
International Journal of Cancer|November 30, 2020
Adjunctive testing by cytology, p16/Ki-67 dual-stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen-positive womenLeticia Torres-Ibarra, Attila T Lorincz, Cosette M Wheeler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancerJack Cuzick, Mitch Dowsett, Silvia Pineda, et al.
Cancer|February 12, 2002
Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United KingdomDavid R Scott, Bjorn Hagmar, Peter Maddox, et al.
BMJ (Clinical Research Ed.)|October 15, 2008
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyJoakim Dillner, Matejka Rebolj, Philippe Birembaut, et al.
Elife|September 5, 2018
Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and deathHaley Hieronymus, Rajmohan Murali, Amy Tin, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
Pageof 37

Showing results (271-280 of 367) with videos related to

Sort By:
Pageof 37
NPJ Breast Cancer|February 13, 2021
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®Richard Buus, Zsolt Szijgyarto, Eugene F Schuster, et al.
Proceedings of Spie--The International Society for Optical Engineering|December 20, 2021
The impact of using weight estimated from mammographic images <i>vs</i> self-reported weight on breast cancer risk calculationKalyani P Nair, Elaine F Harkness, Soujanya Gadde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2010
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC studyMitch Dowsett, Jack Cuzick, Christopher Wale, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 23, 2014
Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemopreventionD Gareth Evans, Adam R Brentnall, Michelle Harvie, et al.
International Journal of Cancer|November 30, 2020
Adjunctive testing by cytology, p16/Ki-67 dual-stained cytology or HPV16/18 E6 oncoprotein for the management of HPV16/18 screen-positive womenLeticia Torres-Ibarra, Attila T Lorincz, Cosette M Wheeler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancerJack Cuzick, Mitch Dowsett, Silvia Pineda, et al.
Cancer|February 12, 2002
Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United KingdomDavid R Scott, Bjorn Hagmar, Peter Maddox, et al.
BMJ (Clinical Research Ed.)|October 15, 2008
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort studyJoakim Dillner, Matejka Rebolj, Philippe Birembaut, et al.
Elife|September 5, 2018
Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and deathHaley Hieronymus, Rajmohan Murali, Amy Tin, et al.
Breast Cancer Research and Treatment|May 2, 2019
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy aloneIvana Sestak, Miguel Martín, Peter Dubsky, et al.
Pageof 37